SMEs burn a year assuming an EU CPSR plus a US listing will unlock China. No. 59 exists specifically so that is not true.
Members Compare markets
CNEUUS
New ingredients, three doors: China NCI, EU annex, US substantiation
Owner takeaway
If the INCI is new in China, it is an NCI project under No. 59 from 15 July 2026. Budget it separately.
EU: check annexes first; an SCCS opinion is not permission.
US: no pre-market ingredient annex. You still need substantiation and an honest listing.
Do not time a global launch off the fastest of the three doors.
Why this now
China No. 59 applied 15 July 2026 while EU annexes and US listing kept moving.
Who is affected
Brands with a 2026–27 “hero active” they want in CN + EU + US.
What to do
Monitor
NCI status in China; SCCS/annex in EU; listing accuracy in US.
Prepare
Split the Gantt: NCI / annex / substantiation as three workstreams.
Act
Do not file a China finished product that depends on an unapproved NCI.
Analysis
Unlock full analysis
Owner takeaway stays free. Choose a plan on the membership page to read the full decision memo comfortably — paid plans also include Workbench and Verify credits.
Sources & related
Linked news
Regulation hubs
Track updates in Workbench, or upgrade for full Regulatory Details and follow-up tools.